Day: April 27, 2021

DENTAL

A Long-term Solution to Missing Teeth (Sponsored)

The long-term solution to your missing teeth

More people are getting dental implants to replace missing teeth. Dental implants are a long-term solution because they are imbedded in your jawbone – just like your natural teeth. They even do your natural teeth one better since they can’t develop cavities. Plus, unlike fixed bridges or removable dentures, dental implants will not affect neighboring healthy teeth or lead to bone loss in the jaw. If properly cared for, dental implants can last a lifetime.

dental implants

Components of a Dental Implant:

  1. Titanium implant
  2. The abutment
  3. The crown

Benefits of Dental Implants:

  • No diet restrictions.
  • Bone preservation because implants are imbedded into the jaw, preventing bone loss.
  • Do not affect neighboring teeth.
  • Look like natural teeth.
  • No day-to-day frustrations or discomfort from ill-fitting dentures.
  • Dental implants can last a lifetime! On average, bridges and dentures need to be replaced every 7 to
Read More Read More
TREATMENT

Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the Treatment of Depression and Addiction

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has successfully demonstrated Proof of Concept for its deuterated tryptamine programs, CYB003 and CYB004, for the treatment of depression and addiction.

Multiple long-acting psychedelic treatments have been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (“FDA”). However, these potential treatments produce psychedelic effects that can last for extended periods of time, presenting challenges to patient access and potentially to payer reimbursement. To overcome these scalability issues, Cybin is working to optimize the duration of action of its treatments through the selective deuteration of several short-acting psychedelic tryptamines.

“This Proof-of-Concept data provides strong support for progressing Cybin’s drug development candidates, CYB003 and CYB004, towards investigational new drug (“IND”) filings with the FDA,” stated Doug Drysdale, CEO of Cybin.

An evaluation of

Read More Read More